Amgen is a biotechnology company focused on developing and manufacturing innovative therapies for serious illnesses. Its core products include biologic medicines for cancer, kidney disease, and inflammatory disorders. Major business segments encompass oncology, nephrology, and inflammation, with primary revenue sources derived from sales of its flagship drugs, including Enbrel and Neulasta. The company also invests in research and development to expand its product pipeline.
The investment profile of Amgen is more aligned with dividends and value investors, given its consistent dividend yield and established market presence. The stock exhibits moderate volatility and has shown resilience in its earnings, making it suitable for those seeking stable returns. Investors may consider a medium to long-term horizon for potential growth, while the liquidity is moderate, reflecting a balanced approach to investment.
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-06-05 02:54 | Vender | Mantener | Mixed performance; monitor for recovery signals. |
| 2026-06-03 02:59 | Mantener | Vender | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-26 03:40 | Vender | Mantener | Weak fundamentals and mixed momentum signal caution. |
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2026-06-09 20:37 | Morgan Stanley | Objetivo aumentado | — → 340 | 344.565 |
| 2026-06-05 12:52 | Goldman Sachs | Objetivo reducido | 425 → 389 | 352.62 |
| 2026-05-14 10:58 | Piper Sandler | Objetivo reducido | 432 → 427 | 336.45 |
